If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

PuriCore Aqualox EPA confirmation

17 Jan 2012 07:00

RNS Number : 6560V
PuriCore Plc
17 January 2012
 



PuriCore's Aqualox® System Confirmed for Use by EPA

 

Proven Effective, Green Biocide Targets Frac Water

 

 

MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 17 January 2012 - PuriCore(LSE: PURI), the water-based clean technology company, today announces it has received confirmation from the US Environmental Protection Agency (EPA) for its Aqualox System as an oil and gas biocide. The Aqualox System generates on-site a proprietary, environmentally safe biocidal solution formulated for applications including in the oil and gas industry to treat hydraulic fracturing (or frac) water, which is used to open deep subterranean natural gas reserves. Aqualox is a highly effective biocide that does not damage fracking stimulation fluids and gel agents or cause corrosion.

 

Christopher Wightman, Executive Chairman, said:

"The potential for hydraulic fracturing (or fracking) to transform the US oil and gas industry is well known. Also well documented are the environmental concerns attaching to the process. We believe that our environmentally benign technology has a major role to play in this industry, and this approval confirms these environmental credentials. As we have developed our technology over recent years, we are now in a position to commercialise it in respect to the oil and gas industry, and will seek to do so during 2012."

 

Enquiries:

FTI Consulting

 +44 (0) 20 7831 3113

Susan Quigley

Ben Brewerton

 

 

About PuriCore

PuriCore plc (LSE: PURI) is a water-based clean technology company focused on developing and commercialising proprietary green solutions that safely, effectively and naturally kill infectious pathogens without causing harm to human health or the environment. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, and wound care. The Company's solutions are proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of C.difficile, E.coli, HIV, Human and Animal Influenza (including H1N1 and H5N1), Legionella, MRSA, M.tuberculosis, Norovirus, and Salmonella. PuriCore is headquartered in Malvern, Pennsylvania, with operations in Stafford and Clevedon, UK.

 

To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCVQLFFLFFZBBB
Date   Source Headline
1st Feb 20199:12 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
31st Jan 201910:06 amRNSForm 8.5 (EPT/RI) - Realm Therapeutics Plc
29th Jan 201910:19 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
25th Jan 20198:55 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
22nd Jan 20199:10 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
14th Jan 20199:44 amRNSForm 8.5 (EPT/RI) - Realm Therapeutics Plc
11th Jan 20199:39 amRNSForm 8.5 (EPT/RI) - Realm Therapeutics Plc
8th Jan 201910:41 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
4th Jan 20199:46 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
3rd Jan 20199:53 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
2nd Jan 20199:26 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
27th Dec 201810:47 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
24th Dec 201810:18 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
21st Dec 201810:26 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
20th Dec 201810:26 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
20th Dec 20188:54 amRNSForm 8.3 - Realm Therapeutics plc
19th Dec 201810:27 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
13th Dec 20189:35 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
10th Dec 20181:20 pmRNSForm 8.3 - Realm Therapeutics plc
10th Dec 201810:32 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
6th Dec 201810:46 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
5th Dec 20189:56 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
4th Dec 201812:20 pmRNSForm 8.5 (EPT/RI) Realm therapeutics
3rd Dec 201811:20 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
30th Nov 20184:08 pmRNSHolding(s) in Company
30th Nov 20181:18 pmRNSForm 8.3 - Realm Therapeutics plc
30th Nov 201811:39 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
29th Nov 201811:58 amRNSHolding(s) in Company
29th Nov 201811:13 amRNSForm 8.3 - Realm Therapeutics plc
29th Nov 20189:55 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
29th Nov 20187:00 amRNSUpdate on Strategic Review
28th Nov 201810:19 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
28th Nov 20189:53 amRNSForm 8.3 - Realm Therapeutics plc
27th Nov 20186:28 pmRNSForm 8.3 - Realm Therapeutics plc
26th Nov 201811:22 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
26th Nov 20188:41 amRNSForm 8.3 - Realm Therapeutics plc
12th Nov 20188:32 amRNSForm 8.5 (EPT/RI) Realm therapeutics
7th Nov 20185:14 pmRNSHolding(s) in Company
7th Nov 201810:37 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
7th Nov 20189:03 amRNSForm 8.3 - Realm Therapeutics plc
6th Nov 201810:36 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
2nd Nov 201811:31 amRNSForm 8.3 - Realm Therapeutics plc
31st Oct 20189:04 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
25th Oct 20189:34 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
19th Oct 201810:23 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
17th Oct 201810:37 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
16th Oct 20189:31 amRNSForm 8.5 (EPT/RI) Realm therapeutics
15th Oct 20189:34 amRNSForm 8.3 - Realm Therapeutics plc
15th Oct 20189:24 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
12th Oct 20188:58 amRNSForm 8.5 (EPT/RI) Realm Therapeutics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.